RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have advanced kidney cancer.
OBJECTIVES: * Determine the response rate of patients with advanced renal cell carcinoma treated with fenretinide. * Determine progression-free and overall survival of this patient population treated with this drug. * Determine the quantitative and qualitative toxic effects of this drug in these patients. OUTLINE: Patients receive oral fenretinide twice a day for 7 days. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. PROJECTED ACCRUAL: Approximately 18-35 patients will be accrued for this study within 9-21 months.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.